AP2011005608A0 - Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside. - Google Patents

Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside.

Info

Publication number
AP2011005608A0
AP2011005608A0 AP2011005608A AP2011005608A AP2011005608A0 AP 2011005608 A0 AP2011005608 A0 AP 2011005608A0 AP 2011005608 A AP2011005608 A AP 2011005608A AP 2011005608 A AP2011005608 A AP 2011005608A AP 2011005608 A0 AP2011005608 A0 AP 2011005608A0
Authority
AP
ARIPO
Prior art keywords
hcv
nucleoside
synergistic combinations
macrocyclic inhibitor
macrocyclic
Prior art date
Application number
AP2011005608A
Other languages
English (en)
Inventor
Tse-I Lin
Oliver Lenz
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of AP2011005608A0 publication Critical patent/AP2011005608A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2011005608A 2008-09-18 2009-09-18 Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside. AP2011005608A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164612 2008-09-18
PCT/EP2009/062096 WO2010031829A1 (fr) 2008-09-18 2009-09-18 Combinaisons synergiques d'un inhibiteur macrocyclique du virus de l'hépatite c et d'un nucléoside

Publications (1)

Publication Number Publication Date
AP2011005608A0 true AP2011005608A0 (en) 2011-04-30

Family

ID=40076811

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005608A AP2011005608A0 (en) 2008-09-18 2009-09-18 Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside.

Country Status (20)

Country Link
US (1) US20110171174A1 (fr)
EP (1) EP2341907A1 (fr)
JP (1) JP2012502956A (fr)
KR (1) KR20110054056A (fr)
CN (1) CN102164602A (fr)
AP (1) AP2011005608A0 (fr)
AR (1) AR073603A1 (fr)
AU (1) AU2009294622A1 (fr)
BR (1) BRPI0919404A2 (fr)
CA (1) CA2737835A1 (fr)
CO (1) CO6351740A2 (fr)
EA (1) EA201170456A1 (fr)
EC (1) ECSP11010902A (fr)
IL (1) IL211599A0 (fr)
MX (1) MX2011002896A (fr)
PA (1) PA8842901A1 (fr)
TW (1) TW201023858A (fr)
UY (1) UY32128A (fr)
WO (1) WO2010031829A1 (fr)
ZA (1) ZA201102047B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
JP5539363B2 (ja) 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
KR20130057990A (ko) * 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 마크로사이클릭 ｈｃｖ 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물
WO2011153712A1 (fr) * 2010-06-12 2011-12-15 Theracos, Inc. Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
WO2012040124A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
CA2813093A1 (fr) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Therapie combinee pour le traitement d'une infection par le vhc
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
RS55592B1 (sr) 2012-10-19 2017-06-30 Bristol Myers Squibb Co 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
KR102327888B1 (ko) * 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2018017989A1 (fr) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Schémas de polythérapie pour le traitement de génotypes du vhc

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
EP1981523A2 (fr) * 2006-02-09 2008-10-22 Schering Corporation Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
EP2341907A1 (fr) 2011-07-13
JP2012502956A (ja) 2012-02-02
ZA201102047B (en) 2012-08-29
KR20110054056A (ko) 2011-05-24
UY32128A (es) 2010-03-26
AR073603A1 (es) 2010-11-17
BRPI0919404A2 (pt) 2015-12-15
PA8842901A1 (es) 2010-04-21
IL211599A0 (en) 2011-05-31
CN102164602A (zh) 2011-08-24
EA201170456A1 (ru) 2011-08-30
CO6351740A2 (es) 2011-12-20
CA2737835A1 (fr) 2010-03-25
TW201023858A (en) 2010-07-01
ECSP11010902A (es) 2011-06-30
AU2009294622A1 (en) 2010-03-25
US20110171174A1 (en) 2011-07-14
MX2011002896A (es) 2011-08-15
WO2010031829A1 (fr) 2010-03-25

Similar Documents

Publication Publication Date Title
AP2011005608A0 (en) Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside.
IL192732A0 (en) Ang2 and vefg inhibitor combinations
HK1154247A1 (en) Hcv nucleoside inhibitor hcv
AP2514A (en) HIV reverse transcriptase inhibitors
IL214760A0 (en) Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrpsis and impaired liver function
IL194434A0 (en) Hcv/hiv inhibitors and their uses
HK1140616A1 (en) Pich-hs timing and operation pich-hs
IL195515A0 (en) Macrocyclic oximyl hepatitis c protease inhibitors
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
PL2185198T3 (pl) Inhibitory LOX i L0XL2 oraz ich zastosowania
EP2227770A4 (fr) Inhibiteurs des prolyl hydroxylases
EP2240178A4 (fr) Inhibiteurs de prolylhydroxylase
EP2224926A4 (fr) Inhibiteurs de prolyl hydroxylases
ZA200809448B (en) Enzyme-microbe synergy
ZA200810025B (en) Cox-2 inhibitor
SI2094702T1 (sl) Virusni inhibitorji
PL2052558T3 (pl) Redukowanie czasu przejścia stanu
IL201875A0 (en) Two-component genome flavivirus and uses thereof
ZA201004693B (en) Vortex inhibitor
GB0606809D0 (en) Strikers
EP2036894A4 (fr) Inhibiteur d'aurora
HK1180222A1 (zh) 大環抑制劑、非核苷和核苷的組合
GB0804356D0 (en) Putting and chipping aid
EP2034994A4 (fr) Inhibiteurs de nf- kappa b et leurs utilisations
TWM299526U (en) Chopsticks